home / stock / oncy / oncy news

ONCY News and Press, Oncolytics Biotech Inc. From 10/31/19

Stock Information
Company Name: Oncolytics Biotech Inc.
Stock Symbol: ONCY
Market: NASDAQ
Website: oncolyticsbiotech.com
Menu
ONCY ONCY Quote ONCY Short ONCY News ONCY Articles ONCY Message Board
Get ONCY Alerts

News, Short Squeeze, Breakout and More Instantly...
ONCY - Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye's Clinical Progress

Adlai received National Medical Products Administration approval for phase 3 clinical trials in China SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 31, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered imm...
ONCY - Breast Cancer Awareness Month Arrives with New Teamwork from Biotech Developers on the Way

October 30, 2019 FN Media Group Presents USA News Group Commentary Los Angeles, CA – October 30, 2019 – USA News Group – As October rolled in to welcome the 35 th annual Breast Cancer Awareness Month , hope remains alive as new drugs continue to develop...

ONCY - Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer

Study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer SAN DIEGO, CA and CALGARY, AB and PHILADELPHIA, PA / ACCESSWIRE / October 22, 2019 / Oncolytics Biotech ® Inc. (NASD...

ONCY - Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics' B...
ONCY - Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous delivery Pelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery to tumor tissue ...

ONCY - Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting data from the AWARE-1 study t...

ONCY - Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its President and Chief Executive Officer, Matt Coffey, Ph.D., MBA,...
ONCY - Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will have an oral presentation at the 12 th Annual Interna...

ONCY - Oncolytics Biotech(R) Announces Upcoming Conference Participation

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will be presenting on the Company's pipeline progress, robust ...

ONCY - Oncolytics Biotech(R) Receives Nasdaq Notification Letter

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market...
Previous 10 Next 10